BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33650740)

  • 1. Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group.
    Loaiza-Bonilla A; Benson AB; Grothey A; Karimi M; Klempner SJ; Lin D; Mahtani R; Soares HP
    Oncologist; 2021 Aug; 26(8):651-659. PubMed ID: 33650740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
    Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Traina T; Vogel C
    Clin Breast Cancer; 2020 Jun; 20(3):183-193. PubMed ID: 32014370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition.
    Ebi H; Bando H; Taniguchi H; Sunakawa Y; Okugawa Y; Hatanaka Y; Hosoda W; Kumamoto K; Nakatani K; Yamazaki K
    Cancer Sci; 2020 Oct; 111(10):3962-3969. PubMed ID: 32667108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
    Bent A; Raghavan S; Dasari A; Kopetz S
    Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.
    Malla M; Parikh AR
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):583-601. PubMed ID: 35577710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Tests for Noninvasive Colorectal Cancer Screening.
    Hanna M; Dey N; Grady WM
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):604-616. PubMed ID: 36539002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.
    Sato S; Nakamura Y; Oki E; Yoshino T
    Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
    Petrillo A; Salati M; Trapani D; Ghidini M
    Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of circulating tumour DNA analysis for gastrointestinal cancers.
    Nakamura Y; Shitara K
    ESMO Open; 2020 Jan; 5(Suppl 1):e000600. PubMed ID: 32830648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
    Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.
    Baraniskin A; Van Laethem JL; Wyrwicz L; Guller U; Wasan HS; Matysiak-Budnik T; Gruenberger T; Ducreux M; Carneiro F; Van Cutsem E; Seufferlein T; Schmiegel W
    Eur J Cancer; 2017 Nov; 86():305-317. PubMed ID: 29065378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
    Corti G; Bartolini A; Crisafulli G; Novara L; Rospo G; Montone M; Negrino C; Mussolin B; Buscarino M; Isella C; Barault L; Siravegna G; Siena S; Marsoni S; Di Nicolantonio F; Medico E; Bardelli A
    Clin Colorectal Cancer; 2019 Jun; 18(2):91-101.e3. PubMed ID: 30981604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of circulating tumor DNA for colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia.
    Nagasaka T; Tanaka N; Cullings HM; Sun DS; Sasamoto H; Uchida T; Koi M; Nishida N; Naomoto Y; Boland CR; Matsubara N; Goel A
    J Natl Cancer Inst; 2009 Sep; 101(18):1244-58. PubMed ID: 19700653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.